Growth Momentum Bausch + Lomb reports strong Q2 2026 results with revenue of $1.394 billion (up 8% YoY) and adjusted EBITDA of $246 million (up 28%), signaling healthy demand across eye health categories and potential upsell opportunities in premium products and surgical devices.

Expanded Leadership Board additions including Barbara J. Trebbi and Thomas J. Appio in 2026 suggest strategic governance strengthening and potential emphasis on accelerating growth initiatives, partnerships, and international expansion efforts worth pursuing.

Premium Lens Growth Recent integration with Wavefront Dynamics to enhance premium scleral lens selection points to increased capability in specialized contact lens offerings, creating cross-sell potential to optometrists and eye care providers seeking advanced solutions.

Global Footprint With a global presence in nearly 100 countries and a portfolio of over 400 products, there are scalable opportunities to introduce new ophthalmic pharmaceuticals and OTC solutions to emerging markets and expand channel partnerships.

Tech Enabled Sales Adoption of modern tech stack including Optimizely, iCIMS, Google Cloud and ChatGPT indicates a digitally enabled sales and customer success approach, enabling targeted marketing, streamlined onboarding, and AI-assisted support for clinicians and distributors.